A Phase 1/2a, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria to Evaluate Safety, Tolerability, Kinetics, and Pharmacodynamics

Trial Profile

A Phase 1/2a, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria to Evaluate Safety, Tolerability, Kinetics, and Pharmacodynamics

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs SYNB-1618 (Primary)
  • Indications Phenylketonuria
  • Focus Adverse reactions; First in man
  • Sponsors Synlogic
  • Most Recent Events

    • 18 Apr 2018 Accotrding to a Synlogic media release, first patient has been dosed.
    • 18 Apr 2018 Status changed from planning to recruiting, according to a Synlogic media release.
    • 18 Apr 2018 Accotrding to a Synlogic media release, interim data from the SAD (Part 1) portion is expect in 2018 and the full data is expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top